Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.

Mohan, Nishant; Jiang, Jiangsong; Dokmanovic, Milos; Wu, Wen Jin

Mohan, Nishant; Jiang, Jiangsong; Dokmanovic, Milos; Wu, Wen Jin.

Afiliación

Mohan N; Division of Biotechnology Review and Research 1, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.
Jiang J; Division of Biotechnology Review and Research 1, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.
Dokmanovic M; Division of Biotechnology Review and Research 1, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.
Wu WJ; Division of Biotechnology Review and Research 1, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.

Antib Ther ; 1(1): 13-17, 2018 Aug 31.

Article en En | MEDLINE | ID: mdl-30215054

Palabras clave

HER2; TOP2B; cardiotoxicity; trastuzumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Antib Ther Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google